Skip to search formSkip to main contentSkip to account menu

Response Evaluation Criteria in Solid Tumors Version 1.1

Known as: RECIST 1.1 
A standardized guideline developed by the Response Evaluation Criteria in Solid Tumors (RECIST) Working Group in 2000 and revised in 2009, which is… 
National Institutes of Health

Related topics

Related topics

1 relation
Clinical Data Interchange Standards Consortium Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
O81 IMpower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (ATEZO) monotherapy vs platinum-based chemotherapy (CHEMO) as first-line (1L) treatment in PD-L1–selected…
Background PD-L1/PD-1 inhibitors (CPI) as monotherapy or in combination with platinum-based doublet chemo (± bevacizumab) are 1L… 
2019
2019
Внутриартериальная химиоэмболизация при метастатическом поражении печени у больных колоректальным раком
Aim . To evaluate the efficacy of transarterial chemoembolization in patients with metastases of colorectal cancer in the liver… 
2019
2019
Стереотаксическая лучевая терапия экстракраниальных метастазов почечно-клеточного рака в комбинации с ингибиторами тирозинкиназы и иммунотерапией: первые результаты клинического исследования ib…
Background. Tyrosine kinase inhibitors (TKI) and checkpoint inhibitors (CI) have been established as effective treatment for mRCC… 
2016
2016
Abstract OT2-01-07: A phase 2 open label, multi-center, multinational study investigating the efficacy and safety of GTx-024 on advanced, androgen receptor-positive triple negative breast cancer (AR…
Background: The androgen receptor (AR) is the most highly expressed steroid receptor in breast cancer (BC) with expression seen… 
2016
2016
Abstract P4-14-23: A phase I/II study of the combination of lapatinib and oral vinorelbine in HER2 positive metastatic breast cancer
Background The combination of lapatinib and oral vinorelbine for HER2 positive metastatic breast cancer (MBC) is appealing due to… 
2014
2014
10 most frequently made mistakes with RECIST 1.1: how Radiologist can fail – and how to avoid them
Poster: "ECR 2014 / C-1689 / 10 most frequently made mistakes with RECIST 1.1: how Radiologist can fail – and how to avoid them… 
Review
2013
Review
2013
Abstract OT2-6-04: Dovitinib, a receptor tyrosine kinase inhibitor in combination with fulvestrant in postmenopausal endocrine resistant human epidermal growth factor receptor 2 negative (HER2…
Background: Overcoming endocrine resistance is a critical goal in the treatment of HR+ breast cancer. Emerging in vitro evidence… 
2012
2012
Abstract OT1-1-06: A phase III randomized study of Paclitaxel and Trastuzumab versus Paclitaxel, Trastuzumab and Lapatinib in first line treatment of HER2 positive metastatic breast cancer.
Background: Preclinical studies have shown that dual targeting of the extracellular domain and the kinase domain of HER2 using… 
2012
2012
Comparison of RECIST 1.1, RECIST 1.0 and WHO Criteria for Peripheral Lung Cancer Response to Treatment
Purpose To evaluate the consistency of WHO, RECIST 1.0 and RECIST 1.1 criteria in evaluating peripheral lung cancer, and to… 
2011
2011
P1-17-08: A Phase II Trial of Ganetespib: Efficacy and Safety in Patients (pts) with Metastatic Breast Cancer (MBC).
Background: Heat shock protein 90 (Hsp90) is a molecular chaperone that maintains the stability of a number of key cellular…